نتائج البحث - Sangodkar, Jaya
- يعرض 1 - 20 نتائج من 25
- اذهب إلى الاصفحة التالية
-
1
-
2
-
3
-
4
-
5
-
6
KLF6-SV1 Is a Novel Antiapoptotic Protein That Targets the BH3-Only Protein NOXA for Degradation and Whose Inhibition Extends Survival in an Ovarian Cancer Model حسب DiFeo, Analisa, Huang, Fei, Sangodkar, Jaya, Terzo, Esteban A., Leake, Devin, Narla, Goutham, Martignetti, John A.
منشور في 2009نص -
7
Targeted reduction of KLF6-SV1 restores chemotherapy sensitivity in resistant lung adenocarcinoma حسب Sangodkar, Jaya, DiFeo, Analisa, Feld, Lauren, Bromberg, Romina, Huang, Fei, Terzo, Esteban A., Choudhri, Aisha, Narla, Goutham
منشور في 2009نص -
8
Phosphoproteomics Profiling of Non-Small Cell Lung Cancer Cells Treated with a Novel Phosphatase Activator حسب Wiredja, Danica D., Ayati, Marzieh, Mazhar, Sahar, Sangodkar, Jaya, Maxwell, Sean, Schlatzer, Daniela, Narla, Goutham, Koyutürk, Mehmet, Chance, Mark R.
منشور في 2017نص -
9
PP2A-activating drugs enhance FLT3 inhibitor efficacy through AKT inhibition-dependent GSK-3β-mediated c-Myc and Pim-1 proteasomal degradation حسب Scarpa, Mario, Singh, Prerna, Bailey, Christopher M., Lee, Jonelle K., Kapoor, Shivani, Lapidus, Rena G., Niyongere, Sandrine, Sangodkar, Jaya, Wang, Yin, Perrotti, Danilo, Narla, Goutham, Baer, Maria R.
منشور في 2021نص -
10
Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers حسب Farrington, Caroline C., Yuan, Eric, Mazhar, Sahar, Izadmehr, Sudeh, Hurst, Lauren, Allen-Petersen, Brittany L., Janghorban, Mahnaz, Chung, Eric, Wolczanski, Grace, Galsky, Matthew, Sears, Rosalie, Sangodkar, Jaya, Narla, Goutham
منشور في 2020نص -
11
Direct activation of PP2A for the treatment of tyrosine kinase inhibitor–resistant lung adenocarcinoma حسب Tohmé, Rita, Izadmehr, Sudeh, Gandhe, Sai, Tabaro, Giancarlo, Vallabhaneni, Sanjay, Thomas, Ava, Vasireddi, Neal, Dhawan, Neil S., Ma’ayan, Avi, Sharma, Neelesh, Galsky, Matthew D., Ohlmeyer, Michael, Sangodkar, Jaya, Narla, Goutham
منشور في 2019نص -
12
Sprague Dawley Rag2 null rats created from engineered spermatogonial stem cells are immunodeficient and permissive to human xenografts حسب Noto, Fallon K., Adjan-Steffey, Valeriya, Tong, Min, Ravichandran, Kameswaran, Zhang, Wei, Arey, Angela, McClain, Christopher B., Ostertag, Eric, Mazhar, Sahar, Sangodkar, Jaya, DiFeo, Analisa, Crawford, Jack, Narla, Goutham, Jamling, Tseten Y.
منشور في 2018نص -
13
KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis حسب Narla, Goutham, DiFeo, Analisa, Fernandez, Yolanda, Dhanasekaran, Saravana, Huang, Fei, Sangodkar, Jaya, Hod, Eldad, Leake, Devin, Friedman, Scott L., Hall, Simon J., Chinnaiyan, Arul M., Gerald, William L., Rubin, Mark A., Martignetti, John A.
منشور في 2008نص -
14
Functional role of the KLF6 tumour suppressor gene in gastric cancer حسب Sangodkar, Jaya, Shi, Jiayan, DiFeo, Analisa, Schwartz, Rachel, Bromberg, Romina, Choudhri, Aisha, McClinch, Kim, Hatami, Raheleh, Scheer, Elias, Kremer-Tal, Sigal, Martignetti, John A, Hui, Alex, Leung, WK, Friedman, Scott L, Narla, Goutham
منشور في 2008نص -
15
Targeting ribonucleotide reductase induces synthetic lethality in PP2A-deficient uterine serous carcinoma حسب O’Connor, Caitlin M., Taylor, Sarah E., Miller, Kathryn M., Hurst, Lauren, Haanen, Terrance J., Suhan, Tahra K., Zawacki, Kaitlin P., Noto, Fallon K., Trako, Jonida, Mohan, Arathi, Sangodkar, Jaya, Zamarin, Dmitriy, DiFeo, Analisa, Narla, Goutham
منشور في 2022نص -
16
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells حسب Kauko, Otto, O’Connor, Caitlin M., Kulesskiy, Evgeny, Sangodkar, Jaya, Aakula, Anna, Izadmehr, Sudeh, Yetukuri, Laxman, Yadav, Bhagwan, Padzik, Artur, Laajala, Teemu Daniel, Haapaniemi, Pekka, Momeny, Majid, Varila, Taru, Ohlmeyer, Michael, Aittokallio, Tero, Wennerberg, Krister, Narla, Goutham, Westermarck, Jukka
منشور في 2018نص -
17
Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response حسب Sangodkar, Jaya, Dhawan, Neil S., Melville, Heather, Singh, Varan J., Yuan, Eric, Rana, Huma, Izadmehr, Sudeh, Farrington, Caroline, Mazhar, Sahar, Katz, Suzanna, Albano, Tara, Arnovitz, Pearlann, Okrent, Rachel, Ohlmeyer, Michael, Galsky, Matthew, Burstein, David, Zhang, David, Politi, Katerina, DiFeo, Analisa, Narla, Goutham
منشور في 2012نص -
18
Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors حسب O’Connor, Caitlin M., Leonard, Daniel, Wiredja, Danica, Avelar, Rita A., Wang, Zhizhi, Schlatzer, Daniela, Bryson, Benjamin, Tokala, Eesha, Taylor, Sarah E., Upadhyay, Aditya, Sangodkar, Jaya, Gingras, Anne-Claude, Westermarck, Jukka, Xu, Wenqing, DiFeo, Analisa, Brautigan, David L., Haider, Shozeb, Jackson, Mark, Narla, Goutham
منشور في 2019نص -
19
The highly recurrent PP2A Aα-subunit mutation P179R alters protein structure and impairs PP2A enzyme function to promote endometrial tumorigenesis حسب Taylor, Sarah E., O’Connor, Caitlin M., Wang, Zhizhi, Shen, Guobo, Song, Haichi, Leonard, Daniel, Sangodkar, Jaya, LaVasseur, Corinne, Avril, Stefanie, Waggoner, Steven, Zanotti, Kristine, Armstrong, Amy J., Nagel, Christa, Resnick, Kimberly, Singh, Sareena, Jackson, Mark W., Xu, Wenqing, Haider, Shozeb, DiFeo, Analisa, Narla, Goutham
منشور في 2019نص -
20
Bisphosphonates inactivate human EGFRs to exert antitumor actions حسب Yuen, Tony, Stachnik, Agnes, Iqbal, Jameel, Sgobba, Miriam, Gupta, Yogesh, Lu, Ping, Colaianni, Graziana, Ji, Yaoting, Zhu, Ling-Ling, Kim, Se-Min, Li, Jianhua, Liu, Peng, Izadmehr, Sudeh, Sangodkar, Jaya, Bailey, Jack, Latif, Yathin, Mujtaba, Shiraz, Epstein, Solomon, Davies, Terry F., Bian, Zhuan, Zallone, Alberta, Aggarwal, Aneel K., Haider, Shozeb, New, Maria I., Sun, Li, Narla, Goutham, Zaidi, Mone
منشور في 2014نص